TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement
Brief Summary: CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
B: Arm Label: Tranexamic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Injection
C: Arm Label: Adrenaline; Type: EXPERIMENTAL; Interventions: Drug: Adrenaline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adrenaline; Assigned to Arm(s): Adrenaline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fibrin Pad | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: SURGICEL™ | Intervention Type: DRUG; Name: Fibrin Pad; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: SURGICEL™; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement
Brief Summary: CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: aprotinin or tranexamic acid; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Epsilon-Aminocaproic Acid (EACA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Epsilon-Aminocaproic Acid (EACA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid (Exacyl) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic acid (Exacyl); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement
Brief Summary: CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).


Options:
A: Arm Label: Tranexamic Acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (placebo) | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Normal Saline (placebo); Assigned to Arm(s): Normal Saline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
C: Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: local group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: systemic group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: combined local and systemic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): combined local and systemic, control, local group, systemic group
D: Arm Label: Total Intravenous; Type: EXPERIMENTAL; Interventions: Drug: Propofol | Arm Label: Inhaled Anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Total Intravenous | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Inhaled Anesthetic

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement
Brief Summary: CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
B: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
C: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement
Brief Summary: CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).


Options:
A: Arm Label: Beriplex® P/N; Type: EXPERIMENTAL; Interventions: Biological: Beriplex® P/N (Kcentra) | Arm Label: Fresh frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh frozen plasma | Intervention Type: BIOLOGICAL; Name: Beriplex® P/N (Kcentra); Assigned to Arm(s): Beriplex® P/N | Intervention Type: BIOLOGICAL; Name: Fresh frozen plasma; Assigned to Arm(s): Fresh frozen plasma
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
C: Arm Label: Haemocomplettan® P; Type: ACTIVE_COMPARATOR; Interventions: Biological: Haemocomplettan® P | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline solution | Intervention Type: BIOLOGICAL; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: BIOLOGICAL; Name: Saline solution; Assigned to Arm(s): Saline solution
D: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement
Brief Summary: CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).


Options:
A: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
B: Arm Label: Standard care for post-partum hemorrhage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Arm Label: rFVIIa; Type: EXPERIMENTAL; Interventions: Drug: rFVIIa | Intervention Type: DRUG; Name: rFVIIa; Assigned to Arm(s): rFVIIa | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard care for post-partum hemorrhage
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
D: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement
Brief Summary: CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).


Options:
A: Arm Label: Vitagel; Type: EXPERIMENTAL; Interventions: Device: Vitagel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vitagel; Assigned to Arm(s): Vitagel
B: Intervention Type: DRUG; Name: IV Tranexamic acid 10mg/kg pt body weight; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quixil topical sealant; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
D: Arm Label: Evicel; Type: EXPERIMENTAL; Interventions: Drug: Evicel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Evicel; Assigned to Arm(s): Evicel

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Double Blind Placebo Controlled Study of Sildenafil for Treatment of Serotonergic Reuptake Inhibitor Associated Sexual Dysfunction in Women With Major Depression Treated to Remission
Brief Summary: This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD.


Options:
A: Intervention Type: DRUG; Name: Ebixa (memantine hydrochloride); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cipralex (escitalopram); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: sildenafil; Assigned to Arm(s): N/A
D: Arm Label: Citalopram + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pindolol | Arm Label: Citalopram + pindolol; Type: EXPERIMENTAL; Interventions: Drug: Pindolol | Intervention Type: DRUG; Name: Pindolol; Assigned to Arm(s): Citalopram + pindolol, Citalopram + placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial
Brief Summary: The HOME-trial is a prospective, randomized controlled trial. The purpose of this study is to investigate the effects of metformin HCL in patients with type 2 diabetes mellitus intensively treated with insulin on the quality of the metabolic control of diabetes, the daily dose of insulin, the lipid profile, the blood pressure, the incidence / progression of microvascular and macrovascular complications, and on the qualify of life (Diabetes Health Profile). Early results had been published in Diabetes Care, December 2002, pages 2133-2140.


Options:
A: Intervention Type: DRUG; Name: Metformin on top of intensive insulin therapy; Assigned to Arm(s): N/A
B: Arm Label: Oral Eligen® B12; Type: EXPERIMENTAL; Interventions: Other: Vitamin B12 (cyanocobalamin) | Arm Label: IM B12; Type: ACTIVE_COMPARATOR; Interventions: Other: Vitamin B12 (cyanocobalamin) | Intervention Type: OTHER; Name: Vitamin B12 (cyanocobalamin); Assigned to Arm(s): IM B12, Oral Eligen® B12
C: Arm Label: i.m. injection of Vitamin B12; Type: ACTIVE_COMPARATOR; Interventions: Drug: i.m. injection of vitamin B12 | Arm Label: Oral administration of vitamin B12; Type: EXPERIMENTAL; Interventions: Drug: Oral administration of vitamin B12 | Intervention Type: DRUG; Name: Oral administration of vitamin B12; Assigned to Arm(s): Oral administration of vitamin B12 | Intervention Type: DRUG; Name: i.m. injection of vitamin B12; Assigned to Arm(s): i.m. injection of Vitamin B12
D: Arm Label: oral Cobalamin (vitamin B12); Type: EXPERIMENTAL; Interventions: Drug: oral Cobalamin (vitamin B12) | Arm Label: intramuscular Cobalamin (vitamin B12); Type: EXPERIMENTAL; Interventions: Drug: intramuscular Cobalamin (vitamin B12) | Intervention Type: DRUG; Name: oral Cobalamin (vitamin B12); Assigned to Arm(s): oral Cobalamin (vitamin B12) | Intervention Type: DRUG; Name: intramuscular Cobalamin (vitamin B12); Assigned to Arm(s): intramuscular Cobalamin (vitamin B12)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial
Brief Summary: The HOME-trial is a prospective, randomized controlled trial. The purpose of this study is to investigate the effects of metformin HCL in patients with type 2 diabetes mellitus intensively treated with insulin on the quality of the metabolic control of diabetes, the daily dose of insulin, the lipid profile, the blood pressure, the incidence / progression of microvascular and macrovascular complications, and on the qualify of life (Diabetes Health Profile). Early results had been published in Diabetes Care, December 2002, pages 2133-2140.


Options:
A: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Metformin on top of intensive insulin therapy; Assigned to Arm(s): N/A
C: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
D: Arm Label: SYR-322 (Alogliptin) QD; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Arm Label: Insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): SYR-322 (Alogliptin) QD | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin

Answer: B